CH Basel Balavenkatraman KK: Difference between revisions
From Bioblast
Nirschl Lisa (talk | contribs) No edit summary |
Beno Marija (talk | contribs) No edit summary |
||
Line 6: | Line 6: | ||
|country=Switzerland | |country=Switzerland | ||
|Contact=Balavenkatraman Kamal Kumar | |Contact=Balavenkatraman Kamal Kumar | ||
|MiPNetLab=Grueninger Stephan | |MiPNetLab=Grueninger Stephan | ||
|Team previous=Chiesi Michele | |Team previous=Chiesi Michele, Weiss Alexander | ||
|Status=O2k 2007 – | |Status=O2k 2007 – | ||
|info=[[IOC106]], [[IOC39]] | |info=[[IOC106]], [[IOC39]] |
Latest revision as of 11:39, 14 May 2019
CH Basel Balavenkatraman KK
O2k-Network Lab | Investigator II (iTox-PCS) - Novartis Pharma Ltd., WKL-135.3.21 |
---|---|
Address | Klybeckstr 191, 4057 |
City | Basel |
State/Prov | |
Country | Switzerland |
Weblink | |
Contact | Balavenkatraman Kamal Kumar |
Team | Grueninger Stephan |
Team previous | Chiesi Michele, Weiss Alexander |
Status | O2k 2007 – |
Oroboros Events | IOC106, IOC39 |
Topics |
O2k-Publications
update please
O2k-Abstracts
update please
- Previously CH_Basel_Chiesi M